Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2019-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2019-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-102019913-B1 |
titleOfInvention |
Anti-ceacam1 antibody and use thereof |
abstract |
The present invention relates to an anti-CEACAM1 antibody having improved specific binding ability to CEACAM1 and its use. The anti-CEACAM1 antibody according to the present invention has excellent specific binding ability to CEACAM1, cytotoxic T cells and natural killer cells. It can be usefully used as an anticancer agent and a composition for treating cancer by activating its anticancer immune function. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190063765-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102325944-B1 |
priorityDate |
2017-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |